1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8933233B2 · kind B2 · utility
0Cited by
7References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 29, 2013 |
| Grant date | Jan 13, 2015 |
| Priority date | — |
| Expiry date | Mar 29, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.